A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer

被引：0
|
作者：
Mackay, H
Major, P
Townsley, C
Mackenzie, M
Vincent, M
Degendorfer, P
Tsao, M
Hedley, D
Wright, J
Oza, A
机构：
[1] Princess Margaret Phase II Consortium, Toronto, ON, Canada
[2] NCI, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3109
引用
下载
收藏
页码：222S / 222S
页数：1
相关论文
共 50 条
  • [1] A phase II trial of the proteosome inhibitor PS-341 (Bortezomib; Velcade)in patients with metastatic colorectal cancer.
    Mackay, HJ
    Major, P
    Townsley, C
    Mackenzie, M
    Vincent, M
    Boudreau, T
    Tsao, M
    Hedley, D
    Wright, J
    Siu, L
    Moore, M
    Oza, AM
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6201S - 6201S
  • [2] A phase II trial of PS-341 in metastatic breast cancer (MBC)
    Cristofanilli, M
    Gonzalez-Angulo, AM
    Nealy, KN
    Booser, D
    Pusztai, L
    Walters, RD
    Hortobagyi, GN
    Reuben, J
    Esseltine, D
    Wright, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 220S - 220S
  • [3] A phase II study of the prateasome inhibitor PS-341 in patients (pts) with metastatic breast cancer (MBC)
    Brown, J
    Von Roenn, J
    O'Regan, R
    Bergan, R
    Badve, S
    Rademaker, A
    Feehan, S
    Petersen, J
    Patton, M
    Gradishar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 14S - 14S
  • [4] A phase I trial of the proteosome inhibitor PS-341 in combination with carboplatin in platinum and taxane resistant ovarian cancer patinets
    Landen, C. N., Jr.
    Coleman, R.
    Milam, M. R.
    Johnston, T.
    Iyer, R.
    Gershenson, D. M.
    Ramirez, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
    Shah, MH
    Young, D
    Kindler, HL
    Webb, I
    Kleiber, B
    Wright, J
    Grever, M
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6111 - 6118
  • [6] Proteosome inhibitor PS-341 (velcade) causes cell growth arrest and apoptosis in colorectal carcinomas
    Al-Sanea, N.
    Abdul, Jabbar A.
    Ashad, L.
    Alhomoud, S.
    Al-Jomah, N.
    Ahmed, M.
    Hussain, A.
    Uddin, S.
    Al-Kuraya, K.
    ANNALS OF ONCOLOGY, 2007, 18 : VII32 - VII32
  • [7] PS-341 is active in multiple myeloma: Preliminary report of a phase I trial of the proteasome inhibitor PS-341 in patients with hematologic malignancies.
    Stinchcombe, TE
    Mitchell, BS
    Depcik-Smith, N
    Adams, J
    Elliott, P
    Shea, TC
    Orlowski, RZ
    BLOOD, 2000, 96 (11) : 516A - 516A
  • [8] Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study
    Davis, NB
    Taber, DA
    Ansari, RH
    Ryan, CW
    George, C
    Vokes, EE
    Vogelzang, NJ
    Stadler, WM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 115 - 119
  • [9] Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
    Orlowski, RZ
    Stinchcombe, TE
    Mitchell, BS
    Shea, TC
    Baldwin, AS
    Stahl, S
    Adams, J
    Esseltine, DL
    Elliott, PJ
    Pien, CS
    Guerciolini, R
    Anderson, JK
    Depcik-Smith, ND
    Bhagat, R
    Lehman, MJ
    Novick, SC
    O'Connor, OA
    Soignet, SL
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (22) : 4420 - 4427
  • [10] Phase II trial of the proteasome inhibitor bortezomib (PS-341, Velcade™) in patients with relapsed/refractory multiple myeloma
    不详
    CLINICAL LYMPHOMA, 2003, 4 (01): : 11 - 12
12345